Stock Track | INSILICO Soars 5.06% Intraday on Nomination of 30th AI-Driven Preclinical Drug Candidate

Stock Track05-07

Shares of INSILICO (03696) soared 5.06% during intraday trading on Thursday, marking a significant upward movement for the stock.

The surge followed the company's announcement that its team in the United Arab Emirates has nominated ISM0387, an MTA-cooperative PRMT5 inhibitor targeting glioblastoma, as a preclinical candidate compound. This drug was discovered using the company's proprietary Pharma.AI platform, with the entire early-stage discovery process completed in under 12 months. The nomination represents Insilico Medicine's 30th AI-driven preclinical candidate, highlighting the expansion of its pipeline and the scalability of its AI-enabled drug discovery capabilities across global teams.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104853373?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 11:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104853373","market":"us","top_or_hot":-1,"title":"Stock Track | INSILICO Soars 5.06% Intraday on Nomination of 30th AI-Driven Preclinical Drug Candidate","media":"Stock Track","content":"<p>Shares of INSILICO (03696) soared 5.06% during intraday trading on Thursday, marking a significant upward movement for the stock.</p><p>The surge followed the company's announcement that its team in the United Arab Emirates has nominated ISM0387, an MTA-cooperative PRMT5 inhibitor targeting glioblastoma, as a preclinical candidate compound. This drug was discovered using the company's proprietary Pharma.AI platform, with the entire early-stage discovery process completed in under 12 months. The nomination represents Insilico Medicine's 30th AI-driven preclinical candidate, highlighting the expansion of its pipeline and the scalability of its AI-enabled drug discovery capabilities across global teams.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | INSILICO Soars 5.06% Intraday on Nomination of 30th AI-Driven Preclinical Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | INSILICO Soars 5.06% Intraday on Nomination of 30th AI-Driven Preclinical Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-07 11:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of INSILICO (03696) soared 5.06% during intraday trading on Thursday, marking a significant upward movement for the stock.</p><p>The surge followed the company's announcement that its team in the United Arab Emirates has nominated ISM0387, an MTA-cooperative PRMT5 inhibitor targeting glioblastoma, as a preclinical candidate compound. This drug was discovered using the company's proprietary Pharma.AI platform, with the entire early-stage discovery process completed in under 12 months. The nomination represents Insilico Medicine's 30th AI-driven preclinical candidate, highlighting the expansion of its pipeline and the scalability of its AI-enabled drug discovery capabilities across global teams.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1104853373","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104853373","pubTimestamp":1778123270,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of INSILICO (03696) soared 5.06% during intraday trading on Thursday, marking a significant upward movement for the stock.The surge followed the company's announcement that its team in the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"个股追踪|英矽智能盘中大涨5.06%获第30款AI驱动临床前候选药物提名","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"Shares of INSILICO (03696) soared 5.06% during intraday trading on Thursday, marking a significant upward movement for the stock.The surge followed the company's announcement that its team in the United Arab Emirates has nominated ISM0387, an MTA-cooperative PRMT5 inhibitor targeting glioblastoma, as a preclinical candidate compound. This drug was discovered using the company's proprietary Pharma.AI platform, with the entire early-stage discovery process completed in under 12 months. The nomination represents Insilico Medicine's 30th AI-driven preclinical candidate, highlighting the expansion of its pipeline and the scalability of its AI-enabled drug discovery capabilities across global teams.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104853373","isCrawlerRequest":true}